Q1 Financials this week?Main thing to watch is the cash burn.
Still happy as long as we're below $3MM in monthly burn. Less than $2.5MM even better.
Burn is needed to move projects forward - so - don't think otherwise.
Need meaningful update going into AGM - this is their chance - but I know some things will be pushed out further. What will we learn?
Think back to items from Q4 and update ...
- all cashed up (and now we have $20MM in short term securities - I like that message)
- P2 initiating soon and data suggests drug can deliver action and onset of pain relief required
- P2 risk reduced with Wisdom Teeth addition (if successful, you know what we're expecting to start earlier ... with data in hand)
- IBD with 2 promising drug molecules - lots to unpack here in calendar Q4
- Filed patent for 352 - so when can they talk to this ?
- Binding letter for CITA (so expecting deal complete by November - maybe October if lucky)
- New Chairman - new focus - wnat to hear something about FDA programs as they are in his wheelhouse.
------------
Lots of R&D on the go - what can they tell us ????
Good Luck